
MIST Stock Forecast & Price Target
MIST Analyst Ratings
Bulls say
Milestone Pharmaceuticals Inc. is well-positioned for positive growth, having demonstrated statistically significant improvements in patient-reported outcomes related to etripamil, which suggests strong customer satisfaction and treatment efficacy. The company has increased its estimated market share in PSVT to 35% and achieved a 100% probability of success for its upcoming CARDAMYST program, highlighting confidence in both product performance and market capture. Additionally, successful navigation of regulatory pathways, including FDA agreement for a streamlined Phase 3 program for AFib-RVR, reinforces the potential for robust value creation for shareholders in the near term.
Bears say
Milestone Pharmaceuticals faces a challenging outlook due to the significant competition posed by existing oral rate control therapies, which provide delayed relief compared to etripamil’s rapid-onset action, resulting in uncertainty regarding adoption among patients. Despite the projected peak revenue potential of CARDAMYST being estimated at over $1 billion if approved for PSVT and AFib-RVR, market investors may not fully recognize or appreciate this potential, leading to underpricing of the company's shares. Additionally, the ongoing Phase 2 clinical trial introduces inherent risks that could impact the company's future revenue trajectory and overall market confidence in its product pipeline.
This aggregate rating is based on analysts' research of Milestone Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
MIST Analyst Forecast & Price Prediction
Start investing in MIST
Order type
Buy in
Order amount
Est. shares
0 shares